Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
OREX [NASD]
Orexigen Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.81 Insider Own11.49% Shs Outstand111.54M Perf Week-4.33%
Market Cap591.16M Forward P/E- EPS next Y-0.18 Insider Trans0.13% Shs Float110.65M Perf Month-28.76%
Income-77.70M PEG- EPS next Q-0.20 Inst Own90.00% Short Float15.68% Perf Quarter-21.36%
Sales3.40M P/S173.87 EPS this Y37.00% Inst Trans5.33% Short Ratio7.22 Perf Half Y-10.77%
Book/sh0.41 P/B12.93 EPS next Y-325.00% ROA-64.50% Target Price11.63 Perf Year-11.81%
Cash/sh1.59 P/C3.34 EPS next 5Y- ROE-179.80% 52W Range4.60 - 7.84 Perf YTD-5.86%
Dividend- P/FCF- EPS past 5Y21.90% ROI-63.30% 52W High-32.40% Beta2.72
Dividend %- Quick Ratio7.80 Sales past 5Y102.40% Gross Margin- 52W Low15.22% ATR0.39
Employees50 Current Ratio7.80 Sales Q/Q0.00% Oper. Margin- RSI (14)33.33 Volatility7.95% 6.91%
OptionableYes Debt/Eq1.91 EPS Q/Q48.80% Profit Margin- Rel Volume0.58 Prev Close5.38
ShortableYes LT Debt/Eq1.91 EarningsMay 05 Payout- Avg Volume2.40M Price5.30
Recom1.90 SMA20-13.95% SMA50-20.19% SMA200-16.42% Volume1,381,617 Change-1.49%
10-Jan-14Initiated WallachBeth Buy $9
03-Oct-13Initiated Cowen Outperform $10
21-Sep-11Upgrade JMP Securities Mkt Perform → Mkt Outperform $5
01-Feb-11Downgrade JMP Securities Mkt Outperform → Mkt Perform
01-Feb-11Downgrade Canaccord Genuity Buy → Hold
03-Dec-10Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform
16-Jul-10Reiterated JMP Securities Mkt Outperform $16 → $13
16-Jul-10Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
02-Feb-10Initiated Jefferies & Co Buy $12
24-Jun-09Initiated Rodman & Renshaw Mkt Outperform $14
13-Mar-09Reiterated Lazard Capital Mkts Buy $13 → $10
03-Apr-08Initiated Cowen & Co Outperform
06-Feb-08Initiated Lazard Capital Buy
04-Feb-08Reiterated Canaccord Adams Buy $29 → $32
03-Jan-08Initiated JP Morgan Overweight
03-Oct-07Upgrade JMP Securities Mkt Outperform → Strong Buy $26
07-Jun-07Initiated JP Morgan Overweight
06-Jun-07Initiated JMP Securities Mkt Outperform $26
14-Apr-14 05:58PM  Biotech Tweet of the Week: Love Being Private at Motley Fool
09:22AM  What Arena's Belviq Television Ad Campaign Means For The Stock at Seeking Alpha
11-Apr-14 04:34PM  Is Orexigen Attractive Near 52-Week Lows? at Seeking Alpha -7.40%
03-Apr-14 12:40PM  VIVUS retreats after analyst cuts rating to sell equivalent at theflyonthewall.com
21-Mar-14 08:49PM  Biotech Tweets of the Week: Gilead Sciences and Orexigen at Motley Fool
19-Mar-14 01:04PM  OREXIGEN THERAPEUTICS, INC. Financials EDGAR Online Financials
13-Mar-14 03:22PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 10-K, Annual Report EDGAR Online
10:13AM  Could Orexigen Therapeutics Be Another Arena or VIVUS? at Motley Fool
10:13AM  Could Orexigen Therapeutics Be Another Arena or VIVUS?
09:17AM  Orexigen looking for FDA approval in next few months, says Cowen at theflyonthewall.com
09:17AM  Orexigen looking for FDA approval in next few months, says Cowen
08:30AM  Narrower Loss at Orexigen in Q4 Zacks
08:30AM  Narrower Loss at Orexigen in Q4
12-Mar-14 11:14PM  Orexigen Therapeutics' CEO Discusses Q4 2013 Results - Earnings Call Transcript at Seeking Alpha
11:14PM  Orexigen Therapeutics' CEO Discusses Q4 2013 Results - Earnings Call Transcript
05:17PM  Orexigen Therapeutics Trims the Fat With a 34% Narrower Q4 Loss at Motley Fool
05:17PM  Orexigen Therapeutics Trims the Fat With a 34% Narrower Q4 Loss
05:00PM  Orexigen Therapeutics, Inc. Earnings Call scheduled for 5:00 pm ET today CCBN
04:55PM  Orexigen Therapeutics, Inc. Discusses Q4 2013 Results (Webcast) at Seeking Alpha
04:55PM  Orexigen Therapeutics, Inc. Discusses Q4 2013 Results (Webcast)
04:33PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
04:01PM  Orexigen Therapeutics Reports Corporate and Financial Results for the Fourth Quarter and Year Ended December 31, 2013 PR Newswire
07:07AM  Q4 2013 Orexigen Therapeutics, Inc. Earnings Release - After Market Close CCBN
11-Mar-14 06:32PM  Lightning Round: Boston Scientific, Sonic & More at CNBC
04-Mar-14 02:01PM  Biotech Showdown: MannKind Corp. vs. Orexigen Therapeutics at Motley Fool
03-Mar-14 08:30AM  Orexigen Therapeutics to Host Full Year and Fourth Quarter 2013 Financial Results Conference Call and Webcast PR Newswire
08:00AM  Celladon Corporation Announces Appointments of Dr. Peter Honig and Dr. Patrick Yang to Its Board of Directors GlobeNewswire
27-Feb-14 08:30AM  Orexigen Therapeutics to Present at the 34th Annual Cowen and Co. Health Care Conference PR Newswire
01:49AM  Arena Earnings On Tap at Seeking Alpha
26-Feb-14 12:22AM  Orexigen Sees Positives In European Application For Contrave at Seeking Alpha
12:01AM  Arena Pharmaceuticals, Inc. Earnings: What to Expect Thursday at Motley Fool
25-Feb-14 08:32PM  Why SINA, VIVUS, and Tenet Healthcare Tumbled Today at Motley Fool
04:48PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events EDGAR Online
09:01AM  Moving Average Crossover: Great News Orexigen Therapeutics (OREX)? Zacks
08:00AM  Orexigen Provides Update on Its NB32 European Marketing Authorization Application PR Newswire
24-Feb-14 04:49PM  Cheaper Obesity Drugs Available (for Half of Some Americans) at Motley Fool
21-Feb-14 08:21AM  GC Aesthetics raises $60M to Fund Global Growth and New Product Development CNW Group
07:40AM  GC Aesthetics raises $60M to Fund Global Growth and New Product Development PR Newswire
14-Feb-14 06:31PM  Why Arena Pharmaceuticals, Inc. Investors Should Remain Wary at Motley Fool
09:16AM  You Should Be Cautious Investing In Orexigen And Arena at Seeking Alpha
09:15AM  Arena Pharmarceuticals and Chelsea Therapeutics International Ltd Could Be Today's Biggest Movers in Healthcare at Motley Fool
11-Feb-14 07:31AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
10-Feb-14 09:27AM  Arena Reaches Critical Point On Insurance Coverage at Seeking Alpha
06-Feb-14 08:30AM  Orexigen Therapeutics to Present at Upcoming Investor Conferences PR Newswire -6.09%
31-Jan-14 02:09PM  Arena's Belviq Sees Traction Slip Ahead Of Advertising at Seeking Alpha
02:09PM  Arena's Belviq Sees Traction Slip Ahead Of Advertising
24-Jan-14 03:54PM  Arena Investors Await Strong Sales Data at Seeking Alpha
03:54PM  Arena Investors Await Strong Sales Data
18-Jan-14 02:07PM  Will Orexigen Win the Obesity Drug War? at Motley Fool
02:07PM  Will Orexigen Win the Obesity Drug War?
17-Jan-14 12:20PM  JPMorgan Healthcare Conference Highlights: Arena Pharmaceuticals, Inc. at Motley Fool
15-Jan-14 06:32PM  VIVUS, Inc. and Aetna Inc's New Weight Loss Plan at Motley Fool
06:32PM  VIVUS, Inc. and Aetna Inc's New Weight Loss Plan
04:02AM  Arena Pharmaceuticals: 4 Different Insiders Have Sold Shares This Year at Seeking Alpha
04:02AM  Arena Pharmaceuticals: 4 Different Insiders Have Sold Shares This Year
14-Jan-14 04:50PM  Orexigen Therapeutics' CEO Presents at JPMorgan Healthcare Conference (Transcript) at Seeking Alpha +7.39%
04:50PM  Orexigen Therapeutics' CEO Presents at JPMorgan Healthcare Conference (Transcript)
10:29AM  J.P. Morgan Healthcare Confab Live Blog: Day Two at TheStreet
10:29AM  J.P. Morgan Healthcare Confab Live Blog: Day Two
13-Jan-14 06:08AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
06:08AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
10-Jan-14 06:31AM  Coverage initiated on Orexigen Therapeutics by WallachBeth Briefing.com
06:31AM  Coverage initiated on Orexigen Therapeutics by WallachBeth
09-Jan-14 11:55AM  Bullish Two Hundred Day Moving Average Cross - OREX at TheStreet
11:55AM  Bullish Two Hundred Day Moving Average Cross - OREX
07-Jan-14 04:22PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events EDGAR Online
04:22PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events
02:36PM  Orexigen Receives Good News From FDA at Seeking Alpha
02:36PM  Orexigen Receives Good News From FDA
09:44AM  [$$] FDA to Decide on Diet Drug by June at The Wall Street Journal
09:44AM  [$$] FDA to Decide on Diet Drug by June
08:09AM  FDA accepts resubmission of Orexigen's Contrave application at theflyonthewall.com
08:09AM  FDA accepts resubmission of Orexigen's Contrave application
08:00AM  Orexigen Announces June 10, 2014 PDUFA Action Date for Contrave PR Newswire
08:00AM  Orexigen Announces June 10, 2014 PDUFA Action Date for Contrave
06-Jan-14 05:09PM  Obesity Stocks Focus On Approvals As Arena Pharmaceuticals Goes Global at TheStreet
05:09PM  Obesity Stocks Focus On Approvals As Arena Pharmaceuticals Goes Global
04:30PM  Orexigen Therapeutics to Present at the J.P. Morgan 2014 Healthcare Conference PR Newswire
04:30PM  Orexigen Therapeutics to Present at the J.P. Morgan 2014 Healthcare Conference
07:58AM  22 Biotech Stock Predictions for 2014 at TheStreet
07:58AM  22 Biotech Stock Predictions for 2014
04-Jan-14 01:25PM  The 7 Healthiest Countries in the World at Motley Fool
01:25PM  The 7 Healthiest Countries in the World
02-Jan-14 12:09PM  Vivus Scores Insurance Win at Seeking Alpha
01-Jan-14 06:09AM  Little-Known $2 Weight Loss Stock Could Double Within 6 Months StreetAuthority Network
31-Dec-13 07:56AM  The 10 Most Common New Year's Resolutions and How They Can Make You Rich at Motley Fool
29-Dec-13 07:04AM  Top Health-Care Stocks for 2014 at Motley Fool
27-Dec-13 03:30PM  Arena, Vivus, and Orexigen: The Obesity Drug Debate Continues at Motley Fool
26-Dec-13 04:14PM  Arena Pharmaceuticals - A 2014 Story at Seeking Alpha
10:45AM  A Not-So Fat 2013 for This Obesity-Drug Maker at Motley Fool
06:24AM  The Obesity Drug Industry Going Into 2014 at Seeking Alpha
24-Dec-13 10:13AM  The 'Real Story' Behind Orexigen Therapeutics, Inc. at Seeking Alpha
13-Dec-13 11:20AM  Update on Orexigen's Contrave Zacks
01:00AM  Orexigen Officially Files FDA Application For Contrave at Seeking Alpha
11-Dec-13 03:36PM  New Obesity Drug Could Be Available in 6 Months at Motley Fool
08:31AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events EDGAR Online
08:00AM  Orexigen Resubmits Contrave New Drug Application PR Newswire
10-Dec-13 01:41AM  Orexigen Completes Financing Deal at Seeking Alpha
09-Dec-13 04:02PM  Orexigen Therapeutics: Light at the End of the Tunnel? at Motley Fool
06:01AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fina EDGAR Online
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates include NB32, which has completed Phase III clinical trials and is being studied in a cardiovascular outcomes trial; and Empatic that has completed Phase II clinical trials. Orexigen Therapeutics, Inc. has collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize NB32 in the United States, Canada, and Mexico. The company was founded in 2002 and is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hagan Joseph PChief Business OfficerJul 31Option Exercise1.6612,00019,92012,000Aug 02 07:34 PM
Hagan Joseph PChief Business OfficerJul 31Sale7.8012,00093,6000Aug 02 07:34 PM
Booth Mark DChief Commercial OfficerJul 26Option Exercise1.6664,767107,51364,767Jul 29 07:50 PM
Hagan Joseph PChief Business OfficerJul 26Option Exercise1.6610,00016,60010,000Jul 29 07:49 PM
Hagan Joseph PChief Business OfficerJul 26Sale7.4010,00074,0000Jul 29 07:49 PM
Booth Mark DChief Commercial OfficerJul 26Sale7.5564,767489,0830Jul 29 07:50 PM
Klassen PrestonSVP, Head Global DevelopmentJul 25Option Exercise1.6671,229118,24071,229Jul 29 07:49 PM
Klassen PrestonSVP, Head Global DevelopmentJul 25Sale7.1671,229510,0000Jul 29 07:49 PM
Klassen PrestonSVP, Head Global DevelopmentMay 28Option Exercise1.6628,77147,76028,771May 30 05:38 PM
Hagan Joseph PChief Business OfficerMay 28Option Exercise1.6628,00046,48028,000May 30 05:38 PM
Hagan Joseph PChief Business OfficerMay 28Sale7.0028,000196,0000May 30 05:38 PM
Klassen PrestonSVP, Head Global DevelopmentMay 28Sale7.2128,771207,3580May 30 05:38 PM